Intensity Therapeutics Inc (INTS) Stock Price, Quote & News

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Industry: Biotechnology

Sector: Healthcare

Phone: 203 221 7381

Fax: 203 557 3023

Website: www.intensitytherapeutics.com

Address:

1 Enterprise Drive, Suite 430, Shelton, United States

Atrain1189 Apr. 17 at 8:39 PM

$INTS just loaded the boat up again here. Quiet with no volume and holding these levels. Maybe news of phase 3 starting soon? Can’t imagine they would want to raise equity at these current prices. Who knows though. Even if it’s drops from here I will keep adding. Easy $20+ stock and could argue $50+

0 · Reply

Pettechfl Apr. 15 at 4:02 PM

$INTS thinking buyout from novartis buy mid next year. if not that then dillution but then I’m going all in after the next drop.

0 · Reply

SBEEE Apr. 15 at 2:20 PM

$INTS

0 · Reply

SBEEE Apr. 15 at 2:08 PM

$INTS https://finance.yahoo.com/news/intensity-therapeutics-recognized-pinnacle-award-131500267.html

0 · Reply

BritishPalaceTrades Apr. 14 at 10:01 PM

$INTS

0 · Reply

SBEEE Apr. 14 at 2:46 PM

$INTS https://www.biopharmaboardroom.com/interaction/1/4546/reprogramming-the-tumor-lew-bender-on-engineering-a-new-paradigm-in-cancer-therapy.html

0 · Reply

TNNSTrade Apr. 8 at 2:44 PM

$INTS 👀 👀 👀

0 · Reply

joel12365 Apr. 7 at 7:04 PM

$INTS Bought a little more and will continue until I see a Proppa re rating and a de risking event

0 · Reply

mikejohns777 Apr. 7 at 5:29 AM

$INTS 💩 💩 💩 Seen this before. Bankruptcy in the future and retail stockholders get shafted.

1 · Reply

haupman Apr. 4 at 11:55 AM

$INTS I think stopping the trial could be a positive if they find a way to only treat patients who can take the 40% absorption, unlike the early trial participants. People who can not take the 40% absorption should not be in this trial.

0 · Reply

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Mar 27, 2026, 4:12 PM EDT - 21 days ago

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Mar 24, 2026, 8:00 AM EDT - 24 days ago

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Mar 12, 2026, 11:15 AM EDT - 5 weeks ago

Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause

Mar 12, 2026, 7:30 AM EDT - 5 weeks ago

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

Mar 6, 2026, 7:47 AM EST - 6 weeks ago

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Feb 13, 2026, 8:58 AM EST - 2 months ago

Intensity Therapeutics Announces Reverse Stock Split

Jan 13, 2026, 7:47 AM EST - 3 months ago

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Dec 11, 2025, 7:47 AM EST - 4 months ago

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Dec 5, 2025, 7:30 AM EST - 4 months ago

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 4, 2025, 7:47 AM EST - 4 months ago

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

Nov 6, 2025, 4:02 PM EST - 5 months ago

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 8:00 AM EDT - 6 months ago

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

$Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal$

Oct 30, 2025, 7:30 AM EDT - 6 months ago

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Sep 10, 2025, 7:47 AM EDT - 7 months ago

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Sep 2, 2025, 7:47 AM EDT - 8 months ago

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:47 AM EDT - 8 months ago

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Aug 7, 2025, 4:06 PM EDT - 9 months ago

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 4, 2025, 7:47 AM EDT - 9 months ago

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Jun 30, 2025, 8:00 AM EDT - 10 months ago

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Jun 11, 2025, 11:46 PM EDT - 11 months ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 4:06 PM EDT - 11 months ago

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jun 11, 2025, 8:30 AM EDT - 11 months ago

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

May 29, 2025, 8:00 AM EDT - 11 months ago

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 28, 2025, 8:00 AM EDT - 11 months ago

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

May 13, 2025, 4:06 PM EDT - 1 year ago

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Mar 13, 2025, 4:07 PM EDT - 1 year ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Jan 28, 2025, 8:00 AM EST - 1 year ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 10, 2025, 8:00 AM EST - 1 year ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Dec 12, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Nov 21, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 18, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 13, 2024, 4:06 PM EST - 1 year ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:19 PM EDT - 1 year ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

May 15, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 10, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 9, 2024, 4:08 PM EDT - 2 years ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 2, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Mar 14, 2024, 4:09 PM EDT - 2 years ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Feb 21, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Jan 3, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Dec 12, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Dec 8, 2023, 8:30 AM EST - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Atrain1189 Apr. 17 at 8:39 PM

0 · Reply

Pettechfl Apr. 15 at 4:02 PM

$INTS thinking buyout from novartis buy mid next year. if not that then dillution but then I’m going all in after the next drop.

0 · Reply

SBEEE Apr. 15 at 2:20 PM

$INTS

0 · Reply

SBEEE Apr. 15 at 2:08 PM

$INTS https://finance.yahoo.com/news/intensity-therapeutics-recognized-pinnacle-award-131500267.html

0 · Reply

BritishPalaceTrades Apr. 14 at 10:01 PM

$INTS

0 · Reply

SBEEE Apr. 14 at 2:46 PM

$INTS https://www.biopharmaboardroom.com/interaction/1/4546/reprogramming-the-tumor-lew-bender-on-engineering-a-new-paradigm-in-cancer-therapy.html

0 · Reply

TNNSTrade Apr. 8 at 2:44 PM

$INTS 👀 👀 👀

0 · Reply

joel12365 Apr. 7 at 7:04 PM

$INTS Bought a little more and will continue until I see a Proppa re rating and a de risking event

0 · Reply

mikejohns777 Apr. 7 at 5:29 AM

$INTS 💩 💩 💩 Seen this before. Bankruptcy in the future and retail stockholders get shafted.

1 · Reply

haupman Apr. 4 at 11:55 AM

0 · Reply

haupman Apr. 4 at 5:01 AM

$INTS I'm thinking to buy but I just can't get over no one is offering them money for a big stake in the company down at these levels. They would be willing to sell 4M shares at $5 and instead they have to do an ATM.

0 · Reply

haupman Apr. 3 at 6:32 PM

$INTS any concerns with the new protocol adjustments could diminish the effectiveness? Does it invalidate all old data?

1 · Reply

SBEEE Apr. 2 at 6:23 PM

$INTS So finally an update on a study today. https://clinicaltrials.gov/study/NCT06358573

1 · Reply

joel12365 Mar. 31 at 8:29 PM

$INTS

0 · Reply

TNNSTrade Mar. 31 at 8:02 PM

$INTS Nice to see some positive action and notes about INTS. Let's get on this horse and ride! 🐎

0 · Reply

mikejohns777 Mar. 30 at 7:19 PM

$INTS This is more likely to go to 1.00 than 10.00

1 · Reply

joel12365 Mar. 27 at 9:27 PM

$INTS WOOOO Tbnc enrollment accepted :) Let’s bloody go Added more

3 · Reply

TNNSTrade Mar. 27 at 8:47 PM

$INTS waiting on news if funding. Let's do this. 👀

0 · Reply

LaffertyDaniel32 Mar. 25 at 2:12 PM

$INTS anyone able to chat about INTS with me? Been in this for a bit - have 17k shares and just want to shoot the sheet with someone who’s knowledgeable. Thanks

1 · Reply

Swerbian Mar. 25 at 3:09 AM

$INTS if they offer before any climb im out

0 · Reply

IggieKooppa Mar. 24 at 8:52 PM

$INTS not yet.. Coming soon.

0 · Reply

TNNSTrade Mar. 24 at 3:22 PM

$INTS I'm pleasantly surprised the increased offering amount hasn't caused a panic. The more money they raise, the better, even if there is a short term hit, which I predict would be the perfect buying opportunity! 👀 Something is coming soon

0 · Reply

Market Cap	13.52M
Revenue (ttm)	0.00
Net Income (ttm)	-11.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	59,700
Avg Vol	49,788
Day's Range	N/A - N/A
Shares Out	2.54M
Stochastic %K	33%
Beta	3.65
Analysts	Strong Sell
Price Target	$27.33